Page 2 - Adeptrix Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Avacta Group PLC, Electronic Communications with Shareholders

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer ® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance ...